

DOCKET NO.: RTS-0274

Date of Deposit: 11/29/01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: William Gaarde et al.

Serial No.: Not yet assigned

Group No.: Not yet assigned

Filed: herewith

For: **Antisense Modulation of Connective Tissue Growth Factor Expression**

BOX SEQUENCE

Assistant Commissioner for Patents
Washington DC 20231

INFORMATION DISCLOSURE STATEMENT


Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above identified application, no additional fee is required.

Copies of each of the references listed on the attached Form PTO-1449 are enclosed.

Date: November 29, 2001

Respectfully submitted,


Donna T. Ward
Registration No. 48,271

ISIS PHARMACEUTICALS, INC.
Carlsbad Research Center
2292 Faraday Avenue
Carlsbad, CA 92008

Date of Deposit: 11/21/2001

| | | | |
|---|----|---|--------------------------------|
| Form PTO-1449 Modified | | Docket No. RTS-0274 | Serial No. not yet assigned |
| List of Patents and Publications Cited by Application (Use several sheets if necessary) | | Applicant William Gaarde et al. | |
| | | Filing Date herewith | Group |
| U.S. Department of Commerce Patent and Trademark Office | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | AA | Allen et al., Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis, Am. J. Respir. Cell Mol. Biol., 1999, 21:693-700 | |
| | AB | Babic et al., Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo, Mol. Cell Biol., 1999, 19:2958-2966 | |
| | AC | Boes et al., Connective tissue growth factor (IGFBP-rP2) expression and regulation in cultured bovine endothelial cells, Endocrinology, 1999, 140:1575-1580 | |
| | AD | Bradham et al., Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10, J. Cell Biol., 1991, 114:1285-1294 | |
| | AE | Duncan et al., Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP, Faseb J., 1999, 13:1774-1786 | |
| | AF | Hishikawa et al., Transforming growth factor-beta(1) induces apoptosis via connective tissue growth factor in human aortic smooth muscle cells, Eur. J. Pharmacol., 1999, 385:287-290 | |
| | AG | Hishikawa et al., Static pressure regulates connective tissue growth factor expression in human mesangial cells, J. Biol. Chem., 2001, 276:16797-16803 | |
| | AH | Hishikawa et al., Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7, J. Biol. Chem., 1999, 274:37461-37466 | |
| | AI | Ito et al., Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis, J. Am. Soc. Nephrol., 2001, 12:472-484 | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|----|---|--------------------------------|
| Form PTO-1449 Modified | | Docket No. RTS-0274 | Serial No. not yet assigned |
| List of Patents and Publications Cited by Application (Use several sheets if necessary) | | Applicant William Gaarde et al. | |
| | | Filing Date herewith | Group |
| U.S. Department of Commerce Patent and Trademark Office | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | AJ | Jedsadayanmata et al., Activation-dependent adhesion of human platelets to Cyr61 and Fisp12/mouse connective tissue growth factor is mediated through integrin alpha(IIb)beta(3), J. Biol. Chem., 1999, 274:24321-24327 | |
| | AK | Kasaragod et al., Connective tissue growth factor expression in pediatric myofibroblastic tumors, Pediatr. Dev. Pathol., 2001, 4:37-45 | |
| | AL | Kim et al., Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily, Proc. Natl. Acad. Sci. U. S. A., 1997, 94:12981-12986 | |
| | AM | Kondo et al., Characterization of a mouse ctgf 3'-UTR segment that mediates repressive regulation of gene expression, Biochem. Biophys. Res. Commun., 2000, 278:119-124 | |
| | AN | Kothapalli et al., Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway, Cell Growth. Differ., 1997, 8:61-68 | |
| | AO | Kubota et al., Involvement of cis-acting repressive element(s) in the 3'-untranslated region of human connective tissue growth factor gene, FEBS Lett., 1999, 450:84-88 | |
| | AP | Lasky et al., Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis, Am. J. Physiol., 1998, 275:L365-371 | |
| | AQ | Lau et al., The CCN family of angiogenic regulators: the integrin connection, Exp. Cell Res., 1999, 248:44-57 | |
| | AR | Lopez-Bermejo et al., Characterization of insulin-like growth factor-binding protein-related proteins (IGFBP-rPs) 1, 2, and 3 in human prostate epithelial cells: potential roles for IGFBP-rP1 and 2 in senescence of the prostatic epithelium, Endocrinology, 2000, 141:4072-4080 | |
| | AS | Martinerie et al., Physical mapping of human loci homologous to the chicken nov proto-oncogene, Oncogene, 1992, 7:2529-2534 | |
| EXAMINER | | DATE CONSIDERED | |

| | | | |
|---|----|--|--------------------------------|
| Form PTO-1449 Modified | | Docket No. RTS-0274 | Serial No. not yet assigned |
| List of Patents and Publications Cited by Application (Use several sheets if necessary) | | Applicant William Gaarde et al. | |
| | | Filing Date herewith | Group |
| U.S. Department of Commerce Patent and Trademark Office | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | AT | Moussad et al., Connective tissue growth factor: what's in a name?, Mol. Genet. Metab., 2000, 71:276-292 | |
| | AU | Nakanishi et al., Overexpression of connective tissue growth factor/hypertrophic chondrocyte-specific gene product 24 decreases bone density in adult mice and induces dwarfism, Biochem. Biophys. Res. Commun., 2001, 281:678-681 | |
| | AV | Pereira et al., Transcriptional regulation of connective tissue growth factor by cortisol in osteoblasts, Am. J. Physiol. Endocrinol. Metab., 2000, 279:E570-576 | |
| | AW | Shimo et al., Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells, J. Biochem. (Tokyo), 1998, 124:130-140 | |
| | AX | Tsubaki et al., Effects of sodium butyrate on expression of members of the IGF-binding protein superfamily in human mammary epithelial cells, J. Endocrinol., 2001, 169:97-110 | |
| | AY | Twigg et al., Advanced glycosylation end products up- regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus, Endocrinology, 2001, 142:1760-1769 | |
| | AZ | Vorwerk et al., CTGF (IGFBP-rP2) is specifically expressed in malignant lymphoblasts of patients with acute lymphoblastic leukaemia (ALL), Br. J. Cancer, 2000, 83:756-760 | |
| | BA | Yang et al., Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-beta in Hs578T human breast cancer cells, J. Clin. Endocrinol. Metab., 1998, 83:2593-2596 | |
| EXAMINER | | DATE CONSIDERED | |

Form PTO-1449 Modified

List of Patents and Publications
Cited by Application
(Use several sheets if necessary)
U.S. Department of Commerce
Patent and Trademark Office

Docket No.
RTS-0274

Serial No.

Applicant
William Gaarde et al.

Filing Date

Group



U.S. PATENT DOCUMENTS

| Examiner's Initial | | Document No. | Date | Name | Class | Subclass |
|--------------------|----|--------------|------------|--------------------|-------|----------|
| | AA | 5,876,730 | 3/2/1999 | Brigstock et al. | 424 | 198.1 |
| | AB | 5,585,270 | 12/17/1996 | Grotendorst et al. | 435 | 252.3 |
| | AC | 5,783,187 | 7/21/1998 | Grotendorst et al. | 424 | 158.1 |
| | AD | 6,150,101 | 11/21/2000 | Grotendorst et al. | 435 | 6 |
| | AE | 6,232,064 | 5/15/2001 | Grotendorst et al. | 435 | 6 |
| | AF | 6,069,006 | 5/30/2001 | Grotendorst et al. | 435 | 325 |
| | AG | | | | | |
| | AH | | | | | |
| | AI | | | | | |
| | AJ | | | | | |
| | AK | | | | | |
| | AL | | | | | |
| | AM | | | | | |
| | AN | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initial | | Document No. | Date | Country | Translation YES NO | |
|--------------------|----|--------------|------------|---------|-----------------------|--|
| | AO | WO 99/66959 | 12/29/1999 | PCT | X | |
| | AP | WO 00/35936 | 6/22/2000 | PCT | X | |
| | AQ | WO 01/29217 | 4/26/2001 | PCT | X | |
| | AR | WO 00/13706 | 3/16/2000 | PCT | X | |
| | AS | WO 00/27868 | 5/18/2000 | PCT | X | |
| | AT | | | | | |
| | AU | | | | | |
| | AV | | | | | |
| | AW | | | | | |
| | AX | | | | | |

EXAMINER

DATE CONSIDERED